Skip to main content

Table 4 Differential expression of putative tumor oncogenes and suppressor genes in melanoma

From: The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis

Oncogenes
Gene Fold Increase Interval of Increase Activating Mechanisms in other Tumor Histologies Affected Tumor Types
SPP-1 13.2 Thin to IM C-Met activation via αvβ3 receptor; Inhibition of apoptosis Breast, HCC, Prostate, CRC, Head & Neck
MITF 3.7 Progressive increase Somatic alteration via gene amplification (Chr.#3p13-3p14) None, Lineage Specific for Melanoma
CITED-1 (cbp/p300 transactivator) 12.4 IM to Thick Activation of Stat-3, Ras/MAPK kinase signaling via Ets1, Ets2 Thyroid
GDF15 (PLAB) 22.7 IM to Thick Lineage specific activation or repression of ERK1/2; Integrator of AKT pathway Breast, CRC, Gastric, Prostate, Pancreatic
c-Met 14.5 Thick to Met Ras-Associated Protein (Rap1)/ERK/MAPK, rac1, Grb2, PI3K, src activation CRC, Breast, Ovarian, Pancreatic, Liver
HOX Locus (A3, A10, B6, B7, B13) 2.1 – 5.0 Progressive increase Downstream activation of WT-1, NFKB, NR4A3, BCL2, p53 AML, Breast, SCLC
Tumor Suppressor Genes
Gene Fold Decrease Interval of Decrease Suppressor Mechanisms in other Tumors Histologies Affected Tumor Types
PITX-1 13.9 Thin to IM Ras Pathway (RASAL1) Barrett's [Esophagus] Prostate, Bladder
CST6 (CST E/M) 66.7 IM to Thick Hypermethylation Breast, Glioma
PDGFRL 7.3 IM to Thick Gene Deletion from Chr.# 8p21.3-p22 HCC, CRC, NSCLC
DSC3 42.8 Progressive decrease Hypermethylation Breast
POU2F3 49 Thin to IM Hypermethylation Cervical
CLCA2 162 MIS/Thin to MM Hypermethylation Breast
  1. Note: Tables represent a partial list of identified tumor oncogenes and tumor suppressor genes (TSG's) in PCM and MM samples. The fold increase represents the greatest fold change noted throughout all comparisons of each PCM tumor thickness to MM. The activating/suppressive mechanism and affected tumor type are also identified. Abbreviations: HCC, hepatocellular carcinoma, CRC, colorectal carcinoma, NSCLC, non-small cell lung cancer, SCLC, squamous cell lung cancer, AML, acute myelogenous leukemia.